{"id":"abacavir-lamivudine-raltegravir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abacavir/lamivudine works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV-1. Raltegravir, on the other hand, targets the integrase enzyme, which is responsible for integrating the viral DNA into the host genome. By inhibiting these enzymes, both drugs prevent the replication of HIV-1 and reduce the viral load in the body.","oneSentence":"Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:35.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of mother-to-child transmission of HIV-1"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT02708342","phase":"","title":"Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2016-04","conditions":"HIV","enrollment":100},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT01900106","phase":"PHASE3","title":"A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)","status":"COMPLETED","sponsor":"University of Modena and Reggio Emilia","startDate":"2013-11","conditions":"HIV Infection","enrollment":47},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00958100","phase":"PHASE2","title":"Raltegravir Switch for Toxicity or Adverse Events","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2009-08","conditions":"HIV/AIDS, Antiretroviral Therapy, HIV Infections","enrollment":40},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00765271","phase":"PHASE1","title":"Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2008-05","conditions":"HIV","enrollment":29},{"nctId":"NCT00740064","phase":"PHASE4","title":"Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects","status":"UNKNOWN","sponsor":"Denver Infectious Disease Consultants, PLLC","startDate":"2008-05","conditions":"HIV Infections","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kivexa","Isentress"],"phase":"phase_3","status":"active","brandName":"abacavir/lamivudine + raltegravir","genericName":"abacavir/lamivudine + raltegravir","companyName":"University of Modena and Reggio Emilia","companyId":"university-of-modena-and-reggio-emilia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}